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abstract

Utilization of clinical technology and mobile health (mHealth) is expanding globally. It is important to reﬂect on
how their usage and application could translate in low- and middle-income country (LMIC) settings. With the
exponential growth and advancements of mobile and wireless technologies, LMICs are prime to adapt such
technologies to potentially democratize and create solutions to health-related challenges. The role of these
technologies in oncology clinical trials continues to expand. The lure of mHealth promises disruptive technology
that may change the way clinical trials are designed and conducted in many settings. Its applicability in the
African context is currently under consideration. Although potentially of expanding beneﬁt, the role of these
technologies requires careful and nuanced evaluation of the context in which they might be applied to harness
their full potential, while mitigating possible harms or preventing further deepening of disparities within populations. Moreover, technology and digital innovations are no substitute for poor referral pathways and dysfunctional health systems and can only complement or enhance deﬁnite strategies aimed at strengthening these
health systems.
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There is an increasing interest and development in the
ﬁeld of mobile health (mHealth) and clinical technology globally. It is important to reﬂect on how its
usage and application could translate in many lowand middle-income country (LMIC) settings. With the
exponential growth and advancements of mobile and
wireless technologies, LMIC countries are prime to
adapt such technologies to democratize and create
solutions to a vast range of issues. With an increasing
number of human populations using a variety of
technology, including mobile phones, laptops, or
tablets, companies involved in clinical trials have
begun to seek ways to deploy and generate data by
leveraging use of these mobile technologies. It is estimated that by 2021, there will be 1.5 million devices
per capita, amounting to a total of 11.6 billion devices,
and the average mobile connection speed globally will
be . 20 megabits/s.1
The role of these technologies in clinical trials and
more speciﬁcally in oncology clinical trials continues to
expand. The lure of mHealth promises disruptive
technology that may change the way clinical trials are
conducted in many settings, and its applicability in
the African context is under consideration. Although
potentially of expanding beneﬁt, the role of these

technologies requires a thorough evaluation of the
context in which they might be applied and in anticipating and minimizing potential barriers or harms to
their use and applicability.
MOBILE PHONE TECHNOLOGY
Globally, the expansion of use of mHealth technologies has been based on a primary parallel expansion of mobile phone users, from , 1 billion in 2000
to . 7 billion in 2015.2 As deﬁned by the WHO,
mHealth involves the use of short messaging services
(SMS); global positioning systems; third-, fourth-,
and now ﬁfth-generation mobile telecommunication systems (3G, 4G, and 5G); as well as general
packet radio service, smart phone applications, and
Bluetooth technology. Which technology is used is
dependent on the geographic area and access to
network in that area. Within mHealth, there have
been various proposed categories of use, some of
which were deﬁned by the WHO and are listed in
Table 1.3
The six types of mHealth technologies identiﬁed by the
WHO include: SMS text messaging, technologies included PDAs and smartphones, patient monitoring
devices, mobile telemedicine/telecare devices, MP3
players, and mobile computing4
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TABLE 1. Use of Mobile Health
Use
Medication compliance
Health promotion and disease prevention
Awareness raising over health issues
Health monitoring and disease surveillance
Communication
Data collection
Mobile telemedicine
Point of care and decision support
Emergency medical response

CURRENT APPLICATIONS OF mHEALTH AND CLINICAL
TECHNOLOGY IN HIGH-RESOURCE COUNTRIES
In 2011, the WHO produced an mHealth report detailing
that higher-income countries showed more mHealth activities than lower-income countries, with countries in the
European region as the most active and those in the African
region as the least active. At the time, although many
countries reported mHealth activity, evaluation of those
activities was low (12%). There was little difference between the number of countries reporting at least one
mHealth initiative between the low-income and highincome groups (77% v 87%). 3
Demonstrated beneﬁts of these technologies may vary
based on the outcome goal. The WHO has recommended
moving from usability as an outcome measure to a health
outcomes–based approach, with randomized controlled
studies and standardized replicable study designs to assist
in standardizing how these technologies are studied. The
growth in experimental applications, however, has demonstrated improvements in increased access to knowledge
and protected health information (PHI), improved timely
access to emergency and general health services, reduced
drug shortages at health clinics, and enhanced clinical
diagnosis and treatment adherence.3
Countries in the high-income group, as denoted by the
WHO, were less likely to use mHealth for surveillance
initiatives and health surveys, most likely because an
existing surveillance capacity already exists in these places.
More often, high-income countries (HICs) used mHealth to
send appointment reminders to improve patient adherence
(eg, missing appointments costs the United Kingdom an
estimated 790 million pounds per year).3
A more recent review of mHealth application areas in HICs
and LMICs by Abaza and Marschollek described newer
apps and technology used.5 Of the 210 studies reviewed,
149 were based in HICs versus 61 in LMICs. The majority of
health monitoring applications focused on NCDs and were
studied in HICs (only 3.6% in LMICs). In the health
monitoring and surveillance technology category, diabetes

apps allowed patients to enter glucometer readings and
send them to the health care provider for personalized
feedback. The outcomes of these evaluation studies focused not only on usability but also on reduced rate of
hospitalizations or decrease in duration of hypoglycemic
events. Apps for NCDs, addiction, and mental health were
more common in HICs. However, the African region did not
have any applications for NCD studies, with apps more
likely being used for communicable diseases, including
HIV and tuberculosis. Even among all the regions studied,
NCDs were the least-studied disease group and cancer the
least-studied among the 4 NCD categories (diabetes, CVD,
respiratory disease, and cancer).5
CURRENT APPLICATIONS OF mHEALTH AND CLINICAL
TECHNOLOGY IN AFRICA AND OPPORTUNITIES FOR
CLINICAL TRIAL USE
Data from the International Telecommunication Union
showed that of the 6 billion mobile phone subscriptions
globally in 2011, . 80% of the 660 million new subscriptions that year were from developing countries.6 The
upsurge of mobile phone use and penetration has resulted
in an increase in availability, more so than infrastructure like
electricity, paved roads, or running water.7,8
A preliminary systematic review of seven mHealth projects
in LMICs suggested a potential improvement in health
communication between patients and health workers.9
Another systematic review of the use of mHealth in
Africa revealed that out of 44 projects conducted in Africa
between 2006 and 2013, 19 were pilot studies and 11 were
randomized controlled trials. The remainder of the studies
were varied and involved mixed-methods, cross-sectional,
cohort, and cost analysis studies and qualitative interviews
and literature reviews.8 Most of the mHealth studies done
during this period focused on infectious diseases like HIV,
tuberculosis, and malaria.
Among the clinical trials done, a number of studies focused
on patient follow-up and adherence to treatment protocols
(n = 8), staff evaluation, monitoring and compliance with
guidelines (n = 2), and data collection/transfer and
reporting. Although these trials may give a sense of the
potential for application in other clinical trials, they were
encumbered by the small size of trials and a lack of
scalability to see how these strategies could perform in
a broader setting.8
The role of mHealth in other study designs has been
demonstrated, and the utility appears around different
functions of patient care in different settings. In Kenya,
a middle-income country, mHealth has been used to
monitor pharmacies and prevent stock-outs of medication, suggesting a possible use in a clinical trial setting.10
A collaborative project in South Africa, an uppermiddle–income country, Project Masilueke sent out 1
million SMS messages per day to subscribers of a local
telecommunications operator and project partner to
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encourage HIV/AIDS testing. Although effective in getting
the information to subscribers, the impact of these messages on behavior change is less well studied.11
mHealth initiatives have also been used to provide staff
support and motivation, especially for health workers
working in remote or difﬁcult-to-access areas. A pilot project
in Botswana showed that it was possible to link specialists
and health care workers to improve diagnostic accuracy and
patient care.12 This project has been replicated in many
academic, training, and clinical centers in Africa, where,
through use of mobile applications like WhatsApp, Listserv,
and so on, health workers are able to link and have discussions around patients. More recently mHealth has
demonstrated the ability to link and integrate capacitybuilding strategies around digital health initiatives.13 Similar models could potentially be developed and expanded to
the clinical trial space.
As relates to oncology and mHealth, a mixed-methods
study in Cape Town, South Africa described the feasibility of mobile phones to improve management of patients
with cervical cancer precancerous lesions.14 In South
Africa, mobile phone penetration is 98%, and the use of
mHealth, speciﬁcally SMS messaging, is increasing. The
authors found support among both providers and patients
for an SMS colposcopy clinic appointment reminder system
as well as the use of mobile phones to convey Papanicolaou
test results (or at least, availability of result). A surprising
barrier to the success of the study was the high loss of
mobile phones (58% had ever lost a phone, 28% had lost
one in the last year). This also brought up questions of
privacy with SMS-based interventions.14
Mobile apps have been increasingly used to provide
support for cancer survivors, which could be a potential
entry point for developing patient-centric clinical trials.
Africa still has the highest health worker deﬁcits, with this
being particularly more acute in oncology. Through the
use of mobile apps, it has now been possible to set up local
or regional virtual tumor boards, where patients and their
treatment plans are discussed comprehensively. A current initiative by the US National Institutes of Health/
National Cancer Institute, project ECHO, ensures discussion around cancer control strategies and virtual tumor
boards for continental participants who can submit and
discuss patients with cancer or initiatives with specialists
from within and without Africa.15 Virtual rounds, such as
the radiation oncology chart rounds facilitated by the
African Organization for Research and Training in Cancer
(AORTIC), help to establish communities of practice and
to engage and discuss complex cases where specialists
might be few.16
All these steps are fundamental to establishing the
frameworks of best clinical practice and patient-centered
strategies through which clinical trials and other research
initiatives can evolve.

CHALLENGES TO THE USE OF TECHNOLOGY IN CLINICAL
TRIALS IN AFRICA
Although mHealth has been in use in several low-income
countries (LICs) for different clinical reasons, there are
close to no reports of its use in clinical trials. The use of
mHealth in clinical trials in HICs has been reported but is
projected to possibly have its biggest impact on clinical
trials by 2030.17 The use of this digital technology has met
with several challenges. Participants of a recent survey
conducted by KNect365 shared their concerns about the
use of mHealth in clinical trials. These involved concerns
around data security and privacy, technical operability,
acceptability, usability, and internet connections, among
others.17
Data Security and Privacy
Clinical trials store participants’ data with PHI that needs
protection and privacy. Given the scarcity of internet
connection, which itself is a challenge to use of mHealth in
LICs, trial participants would be tempted to connect to any
wireless internet connection, even those that are unsecured. This may provide the chance for cyber criminals
who would use PHI for ill reasons. It would be challenging
for the trialists to provide secured internet to all study
participants. Researcher who are looking to use mHealth
need to make sure that participants’ information is protected and access is limited to only authorized users.
A number of strategies have been proposed to counter this,
including setting up frameworks for good data governance
to ensure protection of vulnerable populations, particularly
those in LMICs. These strategies include the development
of “ethical oversight and informed consent processes,”
data protection through the regulation of data access
controls, enhancing the sustainability of ethical data use,
and developing and enacting legislation relevant to data
protection.18
System Integration
Many people in LICs use phones only for calls and text,
meaning that most of these phones may not be suitable to
be used in clinical trials. Most mHealth health care projects/trials come as mobile applications, especially on
smart phones. Smartphone-based research studies can
pose an ethical dilemma, as cost of smartphones and the
cost of connectivity to smartphones may be prohibitive for
a large segment of the population and may lead to selection bias and worsening disparities because of uneven
distribution.19
Even for smartphones, there are different operating systems; hence, there could be an interoperability challenge
among trial participants who have different operating
systems. For a trial to be effective, with easy exchange of
required information, there would be a need to have the
same operating system or a system designed to allow integration with other systems
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Internet Connection
This includes availability, speed, and strength. As mentioned earlier, rates of internet penetration in LICs are still
low. This would be a huge challenge for mHealth projects/
trials that need the use of internet connection for data entry
by study participants and auto-backups. There is a need for
easy access of internet and also strong and high-speed
connections for entry, transmission, and reception of data.
Usability
Health literacy and numeracy are a concern for many
populations in Africa. Individual or general literacy (the
ability to read and write) is comparatively lower in Africa and
invariably has an effect on health literacy. Despite advances
in digital technology, the use of different technologies
frequently demands that one have the ability to read and
write. Although there is a gradual increase in educational
strategies on the continent as part of achieving the sustainable development goals, a signiﬁcant proportion of
populations may face difﬁculties with the use of technology.
In addition, multiple local dialects and languages may
further compound patients’ abilities to use these devices
effectively, as they frequently come in a limited number of
languages, the predominant one being English.
Care must be exercised in the use of mobile technology in
ethically demanding aspects of clinical trials, such as informed consent. However, the use of technology may
mitigate some of these issues and bring new challenges,
such as the 2013 Indian Supreme Court ruling, of recording
the informed consent process on video.20
Usability also refers to the ease of how to learn to use the
mobile application by trial participants with different levels
of education. If an application is difﬁcult to use, then this
might result in poor feedback or inappropriate or wrong
data entry. In addition, there is acceptability challenge,
which concerns the participants, clinicians, and regulatory bodies. Another challenge is ensuring accuracy of
data collection, without which a trial result may not be
reliable.
Research Rigor
Despite the use of mHealth in a number of scenarios, there
is a paucity of data on its potential for scalability. Perhaps
because of its relative novelty, there are a number of pilot
studies that may have shown certain beneﬁts in key areas.
These have sometimes not translated into similar ﬁndings
in randomized trials. The randomized trials have, however,
been few, involving small numbers, which may not necessarily be generalizable to large populations. As the oncology research community in Africa incorporates emerging
research paradigms, such as pragmatic clinical trials and
learning health care systems,21 mobile technology may
deliver more opportunities and perhaps a different set of
challenges than those encountered in traditional clinical
trials. More studies and data are required to determine the

broader and longer-term effects of the use of digital technology in clinical trials and other research studies.
KEYS TO SUCCESSFUL mHEALTH USE
Attempts to deﬁne what constitutes a successful mHealth
project in Africa have been made. Aranda et al8 have
crystallized these down to 4 fundamental principles: the
availability of a good design of the tool, engagement of
stakeholders, the available technology and resources to
support the initiative, and integration of the digital health
initiatives into the health care systems.
Project Design
Even as one thinks of the design, one needs to think
through the devices or tools one intends to use and to
contextualize the tools that one intends to use to one’s
setting. This comes down to acceptability and use of the
devices. Before introducing a digital tool, one needs to be
aware of the characteristics of populations, including health
literacy and numeracy. Irrespective of design, digital
technologies must take into account the unique sociocultural consideration of the population they intend to be
used in. For instance, practices such as the use of a single
phone per household or the phone being under the care of
the household leader could easily hamper the utility of
these devices. Converting applications into local languages
could potentially increase acceptability and usage of these
devices in local settings.
Engagement of Stakeholders
It is important to involve all parties involved in the potential
use and maintenance of these devices early. Developing
strong private-public partnerships and robust multidisciplinary teams has been demonstrated to have good outcomes in execution of mHealth projects.8
Availability of Technology and Support
To ensure longevity and sustainability of digital technology,
systems need to be established to regularly support and
upgrade the existing technology. Building into mHealth
components for capacity building that will train local staff to
maintain and support these technologies can only serve to
enhance and retain successful programs.
Integration Into Existing Health Systems
A critical part of the any digital technology is that it must
successfully be integrated into preexisting health systems
rather than as a standalone device. Most governments may
have a preexisting digital strategy. Getting appropriate buyin from the partners and designing tools that integrate well
and complement existing resources ensures the relevance
of the project and its potential for longevity. Integration of
these various technologies will enable data mining and
analytics from multiple sources. Researchers in Africa must
harness the expanding uptake of mobile technology to
ensure meaningful contribution of this technology to the
dawn of “big data” in Africa and that it will be accessible,
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safe, relevant to the population, and beneﬁcial to health
outcomes.
CONSOLIDATION OF mHEALTH SERVICES: TOWARD
GREATER REPRODUCIBILITY AND GENERALIZABILITY
As mHealth becomes more ubiquitous, there have been
global attempts to streamline and integrate these strategies
into mainstream clinical practice. The WHO has been key in
helping to consolidate these efforts. The WHO has also
been key in developing resources such as handbooks for
the scaling up of digital health initiatives like the monitoring
and evaluation of digital health projects: mHealth Assessment and Planning for Scale (MAPS) Toolkit22 and the
handbook for monitoring and evaluation of digital health.23
Although some of these initiatives were initially aimed at
primarily improving maternal, child, and adolescent health,
they can be expanded to cancer care and other medical
areas. In 2018, there was a World Health Assembly resolution calling for a global strategy on digital health to
support the drive toward universal health coverage in different countries.24 Earlier in 2019, the WHO released the
ﬁrst guidelines with strategies to help strengthen health
systems: “WHO Guideline: Recommendations on Digital
Interventions for Health System Strengthening.”25 These
guidelines provide 10 key recommendations on the potential utility of digital health and how it can be harnessed
and used within health systems as countries strive toward
universal health coverage.
Perhaps of greatest signiﬁcance is the attempt to streamline
the reporting of mHealth projects through the mERAS
model, which was developed by a team at Johns Hopkins
University in 2016. They developed a 16-item checklist for
all mHealth evidence to be reported in keeping with other
trials, such as PRISMA for systematic reviews and CONSORT models for clinical trials. This 16-item checklist looks
at the feasibility, usability, and sustainability of different
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